Neuren Pharmaceuticals Limited announced that Joseph Horrigan has joined the company as Vice President of Clinical Development and Medical Affairs. Horrigan most recently served as Assistant Vice President and Head of Medical Research at Autism Speaks.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.09 AUD | -3.26% | +9.22% | -15.54% |
May. 09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.54% | 1.86B | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- NEU Stock
- News Neuren Pharmaceuticals Limited
- Neuren Pharmaceuticals Limited Appoints Joseph Horrigan as VP Clinical and Medical Affairs